ACU

Rating neutralAI MemoPost-earnings T+3

Acme United

As of 2026-07-28/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-28 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 earnings beat and positive initial reaction • 2026-07-23

Base target: $57 / p=50% prob

Biggest risk

Six-month net income and EPS remained below prior year because of Q1 cost pressure. Tariffs are still affecting margins, MyMedic profitability is seasonal, and integration benefits remain unproven. Coverage and forward estimates are thin.

Invalidation

Break below $45 or thesis failure.

What would change my mind?

Q2 showed broad-based sales growth, improving gross margin, stronger retail activity, and progress integrating MyMedic. The initial earnings reaction was favorable, supporting a cautiously improved near-term setup.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-28

Base target

$57

p=50%

Bull target

$68

p=25%

Bear target

$45

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Gradual tariff-related margin normalization
MyMedic integration and Q4 seasonal profitability
Q2 showed broad-based sales growth, improving gross margin, stronger retail activity, and progress integrating MyMedic.

BearKey bullets

Bank debt less cash increased to $27.3 million as of June 30, 2026.
Low analyst coverage, loose peers, and limited forward estimates reduce confidence in valuation conclusions.
MyMedic profitability is seasonal and concentrated in Q4; integration savings and retail expansion may take time.

WatchKey bullets

Q2 2026 earnings beat and positive initial reaction

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $57 (p=50%)

Target spread vs base: +19% / -21%

Scenario probabilities

Bull Target: $68 (p=25%)Base Target: $57 (p=50%)Bear Target: $45 (p=25%)

Commentary

Tone improved materially after Q2: the company reported record revenue and operating income, and secondary coverage described a strong initial market reaction. However, the six-month earnings decline, persistent tariff exposure, limited analyst revisions, absent social context, and loose peer set support a monitoring view rather than a high-conviction bullish thesis.

As of 2026-07-28 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Gradual tariff-related margin normalization
MyMedic integration and Q4 seasonal profitability

Scenarios

Bull Target (Scenario probability)

$68 / p=25% prob

Base Target (Scenario probability)

$57 / p=50% prob

Bear Target (Scenario probability)

$45 / p=25% prob

Analysis 2026-07-28 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.70

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-23
Q2 2026 earnings beat and positive initial reaction
The SEC-filed earnings release reported Q2 sales of $62.7 million, up 16%, EPS of $1.22, up 5%, comparable sales growth of 8% excluding MyMedic, and gross margin expansion to 42.6% [#SEC-8K-2026-07-23]. Secondary coverage reported EPS above the $0.81 consensus estimate and an initial premarket gain of approximately 12%.
Prob 100.00% • Move 12.00% • Priced-in 90.00%

Short-term Catalysts

Next few weeks

Gradual tariff-related margin normalization
2026-09-30
Management said elevated-tariff inventory continued to pressure U.S. margins but that the impact was lower than in Q1 and should decrease in coming quarters [#SEC-8K-2026-07-23].
Prob 65% • Move 6% • Priced-in 45%

Long-term Catalysts

Months to a year

MyMedic integration and Q4 seasonal profitability
2026-12-31
MyMedic contributed sales but had minimal Q2 earnings impact because profitability is historically concentrated in Q4. Management is pursuing retail expansion, sourcing savings, and overhead reduction [#SEC-8K-2026-07-23].
Prob 60% • Move 10% • Priced-in 45%

Risks

Bank debt less cash increased to $27.3 million as of June 30, 2026.
Low analyst coverage, loose peers, and limited forward estimates reduce confidence in valuation conclusions.
MyMedic profitability is seasonal and concentrated in Q4; integration savings and retail expansion may take time.
Six-month 2026 net income and diluted EPS declined year over year.
Tariff-related costs may continue to pressure margins despite expected improvement.

Peers

Symbol	Summary
BDSX	Same-sector, similarly sized reference, but the packet does not establish a close operating or valuation match.
EMBC	Size-comparable health-care equipment reference; business-model read-through to ACU is limited.
FOCL	Same-sector, similarly sized candidate, but available evidence is insufficient for a clean direct comparison.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-28

Loading AI feed…

Symbol

Summary

BDSX

Same-sector, similarly sized reference, but the packet does not establish a close operating or valuation match.

EMBC

Size-comparable health-care equipment reference; business-model read-through to ACU is limited.

FOCL

Same-sector, similarly sized candidate, but available evidence is insufficient for a clean direct comparison.